microRNA-122与非酒精性脂肪性肝病研究进展*

doi:10.3969/j.issn.1672-5069.2024.05.002

Abstract

Jia Shuangzhen, Wu Tianwei, Wu Jie. MicroRNA-122 in non-alcoholic fatty liver disease[J]. Journal of Practical Hepatology, 2024, 27(5): 646-649.

[1] Han SK, Baik SK, Kim MY. Non-alcoholic fatty liver disease: definition and subtypes. Clin Mol Hepatol, 2023, 29(Suppl): S5-S16.
[2] Paternostro R, Trauner M. Current treatment of non-alcoholic fatty liver disease. J Intern Med, 2022, 292(2): 190-204.
[3] Zhou J, Zhou F, Wang W, et al. Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology, 2020, 71(5): 1851-1864.
[4] Nassir F. NAFLD: mechanisms, treatments, and biomarkers. Biomolecules, 2022, 12(6): 824.
[5] Powell EE, Wong VWS, Rinella M. Non-alcoholic fatty liver disease. Lancet, 2021, 397(10290): 2212-2224.
[6] Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immun, 2018, 141(4): 1202-1207.
[7] Mohr A, Mott J. Overview of microRNA biology. Semin Liver Dis, 2015, 35(1): 003-011.
[8] Ho PTB, Clark IM, Le LTT. MicroRNA-based diagnosis and therapy. Int J Mol Sci, 2022, 23(13): 7167.
[9] Bayraktar E, Bayraktar R, Oztatlici H, et al. Targeting miRNAs and other non-coding RNAs as a therapeutic approach: an update. Non-Coding RNA, 2023, 9(2): 27.
[10] Long JK, Dai W, Zheng YW, et al. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease. Mol Med, 2019, 25(1): 26.
[11] Wang X, He Y, Mackowiak B, et al. MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut, 2021, 70(4): 784-795.
[12] Kunden RD, Khan JQ, Ghezelbash S, et al. The role of the liver-specific microRNA, miRNA-122 in the HCV replication cycle. Int J Mol Sci, 2020, 21(16): 5677.
[13] Möröy T, Etiemble J, Bougueleret L, et al. Structure and expression of hcr, a locus rearranged with c-myc in a woodchuck hepatocellular carcinoma. Oncogene, 1989, 4(1): 59-65.
[14] Faramin Lashkarian M, Hashemipour N, Niaraki N, et al. MicroRNA-122 in human cancers: from mechanistic to clinical perspectives. Cancer Cell Int, 2023, 23(1): 29.
[15] Chien Y, Chang YL, Li HY, et al. Synergistic effects of carboxymethyl-hexanoyl chitosan, cationic polyurethane-short branch PEI in miR122 gene delivery: Accelerated differentiation of iPSCs into mature hepatocyte-like cells and improved stem cell therapy in a hepatic failure model. Acta Biomater, 2015, 13: 228-244.
[16] Parvanak M, Mostafavi-Pour Z, Soleimani M, et al. Mir-122 upregulation and let-7f downregulation combination: The effects on hepatic differentiation of hiPSCs on the PCL-Gel-HA nanofibrous scaffold. J Cell Mol Med, 2022, 26(20): 5235-5245.
[17] Gatfield D, Le Martelot G, Vejnar CE, et al. Integration of microRNA miR-122 in hepatic circadian gene expression. Gene Dev, 2009, 23(11): 1313-1326.
[18] Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res, 2021, 149: 1-61.
[19] Zhao Z, Gao J, Huang S. LncRNA SNHG7 promotes the HCC progression through miR-122-5p/FOXK2 axis. Digest Dis Sci, 2022, 67(3): 925-935.
[20] Ouahed J, Spencer E, Kotlarz D, et al. Very early onset inflammatory bowel disease: a clinical approach with a focus on the role of genetics and underlying immune deficiencies. Nes Nutr Ws, 2020, 26(6): 820-842.
[21] Wei X, Liu H, Li X, et al. Over-expression ofmiR-122 promotes apoptosis of hepatocellular carcinoma via targeting TLR4. Ann Hepatol, 2019, 18(6): 869-878.
[22] Hochreuter MY, Dall M, Treebak JT, et al. MicroRNAs in non-alcoholic fatty liver disease: progress and perspectives. Mol Metab, 2022, 65: 101581.
[23] Xu H, Xu SJ, Xie SJ, et al. MicroRNA-122 supports robust innate immunity in hepatocytes by targeting the RTKs/STAT3 signaling pathway. eLife, 2019, 8: e41159.
[24] Janssen HLA, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection bytargeting MicroRNA. N Engl J Med, 2013, 368(18): 1685-1694.
[25] Johri MK, Lashkari HV, Gupta D, et al. mTORC1 restricts hepatitis C virus RNA replication through ULK1-mediated suppression of miR-122 and facilitates post-replication events. J Gen Virol, 2020, 101(1): 86-95.
[26] Li A, Wu J, Zhai A, et al. HBV triggers APOBEC2 expression through miR-122 regulation and affects the proliferation of liver cancer cells. Int J Oncol, 2019, 55(5): 1137-1148.
[27] Hu Y, Du G, Li G, et al. The miR-122 inhibition alleviates lipid accumulation and inflammation in NAFLD cell model. Arch Physiol Biochem, 2021, 127(5): 385-389.
[28] Dong L, Hou X, Liu F, et al. Regulation of insulin resistance by targeting the insulin-like growth factor 1 receptor with microRNA-122-5p in hepatic cells. Cell Biol Int, 2019, 43(5): 553-564.
[29] Krützfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature, 2005, 438(7068): 685-689.
[30] Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab, 2006, 3(2): 87-98.
[31] Csak T, Bala S, Lippai D, et al. microRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis. Liver Int, 2015, 35(2): 532-541.
[32] Wang L, Tang W, Yan S, et al. Efficient delivery of miR-122 to regulate cholesterol metabolism using a non-covalent peptide-based strategy. Mol Med Rep, 2013, 8(5): 1472-1478.
[33] Yamada H, Ohashi K, Suzuki K, et al. Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease. Clin Chim Acta, 2015, 446: 267-271.
[34] Atic AI, Thiele M, Munk A, et al. Circulating miRNAs associated with nonalcoholic fatty liver disease. Am J Physiol Cell Physiol, 2023, 324(2): C588-C602.
[35] Pirola CJ, Fernández Gianotti T, Castaño GO, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut, 2014, 64(5): 800-812.
[36] 童静, 张珂瓈, 李昌平. 非酒精性脂肪性肝炎患者血清前神经降压素和微小RNA-122水平变化及其诊断脂肪性肝炎的价值探讨. 实用肝脏病杂志, 2024, 27(2): 202-205.
[37] 胡灵溪, 安薪宇, 李妹, 等. 超声衰减参数诊断体检人群脂肪肝临床应用价值分析. 实用肝脏病杂志, 2023, 26(4): 488-491.
[38] Salvoza NC, Klinzing DC, Gopez-Cervantes J, et al. Association of circulating serum miR-34a and miR-122 with dyslipidemia among patients with non-alcoholic fatty liver disease. PLoS One, 2016, 11(4): e0153497.
[39] Wu GY, Rui C, Chen JQ, et al. MicroRNA-122 inhibits lipid droplet formation and hepatic triglyceride accumulation via Yin Yang 1. Cell Physiol Biochem, 2017, 44(4): 1651-1664.
[40] Zhang X, Ma L, Zhai L, et al. Construction and validation of a three-microRNA signature as prognostic biomarker in patients with hepatocellular carcinoma. Int J Med Sci, 2021, 18(4): 984-999.
[41] Leti F, Malenica I, Doshi M, et al. High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis. Transl Res, 2015, 166(3): 304-314.
[42] Chai C, Cox B, Yaish D, et al. Agonist of RORA attenuates nonalcoholic fatty liver progression in mice via up-regulation of microRNA 122. Gastroenterology, 2020, 159(3): 999-1014,e9.

MicroRNA-122 in non-alcoholic fatty liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Li Yanmin, Zhang Wei, Hu Yanyan, et al. Clinical implication of serum TyG, visceral/subcutaneous fat area ratio and cardiac metabolic index in elderly patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2024, 27(5): 697-700.
[2]	Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease(Version 2024) [J]. Journal of Practical Hepatology, 2024, 27(4): 494-510.
[3]	Li Kaiyang, Zhao Qi, Huang Jing, et al. Non-alcoholic fatty liver diseases: Clinical trials registered in Chinese clinical trial registry [J]. Journal of Practical Hepatology, 2024, 27(4): 531-534.
[4]	Nong Xiaoli, Chen Fei, Zhan Haohong, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in individuals for physical examination [J]. Journal of Practical Hepatology, 2024, 27(3): 353-356.
[5]	Sun Shilei, Liu Cuicui, Li Shuguang, et al. Changes of serum fibroblast growth factor-21 and secreted frizzled related protein 5 in patients with non-alcoholic fatty liver disease and T2DM [J]. Journal of Practical Hepatology, 2024, 27(3): 357-360.
[6]	Gao Yang, Zhang Jing, Lu Xuanlin. Changes of serum IL-1RA, CTRP13 and CK-18 levels in patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2024, 27(2): 185-188.
[7]	Li Min, Zhang Li, Zeng Ai, et al.. Liver fibrosis in patients with diabetes mellitus type 2 and non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2024, 27(2): 193-197.
[8]	Zheng Bo, Halida.Xiaerfuhazi, Tan Li. Changes of serum HIF-1α, HMGB1 and adiponectin levels in patients with non-alcoholic fatty liver diseases and their correlation to carotid atherosclerosis [J]. Journal of Practical Hepatology, 2024, 27(2): 198-201.
[9]	Wang Wenchuan, Liang Kuopeng, He Ruiling, et al. Prevalence of non-alcoholic fatty liver diseases in patients with type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2024, 27(1): 40-43.
[10]	Zeng Jing, Fan Jiangao. Natural history of metabolic dysfunction-associated fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(6): 769-772.
[11]	Zhou Jiying, Xie Yuehong, Yu Cuixia. Decreased biochemical response to entecavir anti-viral therapy in patients with chronic hepatitis B and concomitant non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(6): 793-796.
[12]	Lu Rong, Li Hui, Zhang Chao, et al. Efficacy of triglyceride glucose index in predicting severity of patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(6): 805-810.
[13]	Shao Xiaoru, Zhou Xiao, Ge Yingying. Diagnosis of coronary atherosclerotic heart disease in patients with nonalcoholic fatty liver disease by CCTA and¹⁸F-FDG intake [J]. Journal of Practical Hepatology, 2023, 26(6): 811-814.
[14]	Ding Xiaojie, Zhang Yongming, Song Haiyan, et al. Prediction of NAFLD in patients with type 2 diabetes mellitus by NLR and PLR: A preliminary study [J]. Journal of Practical Hepatology, 2023, 26(6): 815-818.
[15]	Wang Zhuoya, Wu Yangpeng, Huang Yitao. Combination therapy of reduced glutathione and herbal medicine compound, Hugan Qingzhi tablet in treatment of patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(6): 823-826.